These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 23134356)

  • 1. Progression of RAS-mutant leukemia during RAF inhibitor treatment.
    Callahan MK; Rampal R; Harding JJ; Klimek VM; Chung YR; Merghoub T; Wolchok JD; Solit DB; Rosen N; Abdel-Wahab O; Levine RL; Chapman PB
    N Engl J Med; 2012 Dec; 367(24):2316-21. PubMed ID: 23134356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of intermittent combined RAF and MEK inhibition in a patient with concurrent BRAF- and NRAS-mutant malignancies.
    Abdel-Wahab O; Klimek VM; Gaskell AA; Viale A; Cheng D; Kim E; Rampal R; Bluth M; Harding JJ; Callahan MK; Merghoub T; Berger MF; Solit DB; Rosen N; Levine RL; Chapman PB
    Cancer Discov; 2014 May; 4(5):538-45. PubMed ID: 24589925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRAF inhibitor-associated ERK activation drives development of chronic lymphocytic leukemia.
    Yaktapour N; Meiss F; Mastroianni J; Zenz T; Andrlova H; Mathew NR; Claus R; Hutter B; Fröhling S; Brors B; Pfeifer D; Pantic M; Bartsch I; Spehl TS; Meyer PT; Duyster J; Zirlik K; Brummer T; Zeiser R
    J Clin Invest; 2014 Nov; 124(11):5074-84. PubMed ID: 25329694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progression of KRAS mutant pancreatic adenocarcinoma during vemurafenib treatment in a patient with metastatic melanoma.
    Grey A; Cooper A; McNeil C; O'Toole S; Thompson J; Grimison P
    Intern Med J; 2014 Jun; 44(6):597-600. PubMed ID: 24946815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cutaneous manifestations of vemurafenib therapy for metastatic melanoma.
    Owen JL; Lopez IE; Desai SR
    J Drugs Dermatol; 2015 May; 14(5):509-10. PubMed ID: 25942671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.
    Larkin J; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Espinosa E; Garbe C; Sileni VC; Gogas H; Miller WH; Mandalà M; Hospers GA; Arance A; Queirolo P; Hauschild A; Brown MP; Mitchell L; Veronese L; Blank CU
    Lancet Oncol; 2014 Apr; 15(4):436-44. PubMed ID: 24582505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
    Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
    Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study.
    McArthur GA; Chapman PB; Robert C; Larkin J; Haanen JB; Dummer R; Ribas A; Hogg D; Hamid O; Ascierto PA; Garbe C; Testori A; Maio M; Lorigan P; Lebbé C; Jouary T; Schadendorf D; O'Day SJ; Kirkwood JM; Eggermont AM; Dréno B; Sosman JA; Flaherty KT; Yin M; Caro I; Cheng S; Trunzer K; Hauschild A
    Lancet Oncol; 2014 Mar; 15(3):323-32. PubMed ID: 24508103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The genesis of Zelboraf: targeting mutant B-Raf in melanoma.
    Davis MJ; Schlessinger J
    J Cell Biol; 2012 Oct; 199(1):15-9. PubMed ID: 23027900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner.
    Joseph EW; Pratilas CA; Poulikakos PI; Tadi M; Wang W; Taylor BS; Halilovic E; Persaud Y; Xing F; Viale A; Tsai J; Chapman PB; Bollag G; Solit DB; Rosen N
    Proc Natl Acad Sci U S A; 2010 Aug; 107(33):14903-8. PubMed ID: 20668238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.
    Nazarian R; Shi H; Wang Q; Kong X; Koya RC; Lee H; Chen Z; Lee MK; Attar N; Sazegar H; Chodon T; Nelson SF; McArthur G; Sosman JA; Ribas A; Lo RS
    Nature; 2010 Dec; 468(7326):973-7. PubMed ID: 21107323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction vemurafenib followed by consolidative radiation therapy for surgically incurable melanoma.
    Seeley AR; De Los Santos JF; Conry RM
    Melanoma Res; 2015 Jun; 25(3):246-51. PubMed ID: 25746037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.
    Su F; Viros A; Milagre C; Trunzer K; Bollag G; Spleiss O; Reis-Filho JS; Kong X; Koya RC; Flaherty KT; Chapman PB; Kim MJ; Hayward R; Martin M; Yang H; Wang Q; Hilton H; Hang JS; Noe J; Lambros M; Geyer F; Dhomen N; Niculescu-Duvaz I; Zambon A; Niculescu-Duvaz D; Preece N; Robert L; Otte NJ; Mok S; Kee D; Ma Y; Zhang C; Habets G; Burton EA; Wong B; Nguyen H; Kockx M; Andries L; Lestini B; Nolop KB; Lee RJ; Joe AK; Troy JL; Gonzalez R; Hutson TE; Puzanov I; Chmielowski B; Springer CJ; McArthur GA; Sosman JA; Lo RS; Ribas A; Marais R
    N Engl J Med; 2012 Jan; 366(3):207-15. PubMed ID: 22256804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vemurafenib.
    Garbe C; Abusaif S; Eigentler TK
    Recent Results Cancer Res; 2014; 201():215-25. PubMed ID: 24756795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vemurafenib (RG67204, PLX4032): a potent, selective BRAF kinase inhibitor.
    Patrawala S; Puzanov I
    Future Oncol; 2012 May; 8(5):509-23. PubMed ID: 22646766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma.
    Bollag G; Hirth P; Tsai J; Zhang J; Ibrahim PN; Cho H; Spevak W; Zhang C; Zhang Y; Habets G; Burton EA; Wong B; Tsang G; West BL; Powell B; Shellooe R; Marimuthu A; Nguyen H; Zhang KY; Artis DR; Schlessinger J; Su F; Higgins B; Iyer R; D'Andrea K; Koehler A; Stumm M; Lin PS; Lee RJ; Grippo J; Puzanov I; Kim KB; Ribas A; McArthur GA; Sosman JA; Chapman PB; Flaherty KT; Xu X; Nathanson KL; Nolop K
    Nature; 2010 Sep; 467(7315):596-9. PubMed ID: 20823850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
    Chapman PB; Hauschild A; Robert C; Haanen JB; Ascierto P; Larkin J; Dummer R; Garbe C; Testori A; Maio M; Hogg D; Lorigan P; Lebbe C; Jouary T; Schadendorf D; Ribas A; O'Day SJ; Sosman JA; Kirkwood JM; Eggermont AM; Dreno B; Nolop K; Li J; Nelson B; Hou J; Lee RJ; Flaherty KT; McArthur GA;
    N Engl J Med; 2011 Jun; 364(26):2507-16. PubMed ID: 21639808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain Metastases.
    Harding JJ; Catalanotti F; Munhoz RR; Cheng DT; Yaqubie A; Kelly N; McDermott GC; Kersellius R; Merghoub T; Lacouture ME; Carvajal RD; Panageas KS; Berger MF; Rosen N; Solit DB; Chapman PB
    Oncologist; 2015 Jul; 20(7):789-97. PubMed ID: 25956405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vemurafenib-induced progression of breast cancer: a case report and review of the literature.
    Novik AV; Protsenko SA; Baldueva IA; Ivantsov AO; Nekhaeva TL; Akhaeva ZY; Yanus GA; Iyevleva AG; Imyanitov EN
    Target Oncol; 2016 Apr; 11(2):235-8. PubMed ID: 26264150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 17-AAG inhibits vemurafenib-associated MAP kinase activation and is synergistic with cellular immunotherapy in a murine melanoma model.
    Joshi SS; Jiang S; Unni E; Goding SR; Fan T; Antony PA; Hornyak TJ
    PLoS One; 2018; 13(2):e0191264. PubMed ID: 29481571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.